| 85.88 0.41 (0.48%) | 10-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 102.67  |
1-year : | 119.92 |
| Resists | First : | 87.9 |
Second : | 102.67 |
| Pivot price | 85.4 |
|||
| Supports | First : | 83.88 |
Second : | 81.4 |
| MAs | MA(5) : | 85.6 |
MA(20) : | 84.67 |
| MA(100) : | 90.27 |
MA(250) : | 91.48 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 60.6 |
D(3) : | 62.6 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 107.19 | Low : | 70.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IRMD ] has closed below upper band by 41.1%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 86.62 - 86.94 | 86.94 - 87.2 |
| Low: | 83.76 - 84.17 | 84.17 - 84.49 |
| Close: | 85.27 - 85.9 | 85.9 - 86.4 |
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Fri, 25 Sep 2026
698 stock units became shares for IRADIMED (NASDAQ: IRMD) director Joe E. Kiani. - Stock Titan
Wed, 23 Sep 2026
IRADIMED (IRMD) Draws Fresh Valuation Focus, Is The Recent Bounce Enough? - Simply Wall Street
Wed, 23 Sep 2026
One-on-one investor meetings with Iradimed's CFO are set for New York - Stock Titan
Tue, 22 Sep 2026
Needham Initiates IRadimed at Hold - marketscreener.com
Tue, 08 Sep 2026
Iradimed director Monty Allen sells $122,621 in stock - Investing.com
Sun, 09 Aug 2026
IRADIMED CORPORATION (NASDAQ:IRMD) Looks Interesting, And It's About To Pay A Dividend - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 13 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 35.1 (%) |
| Held by Institutions | 62.7 (%) |
| Shares Short | 728 (K) |
| Shares Short P.Month | 706 (K) |
| EPS | 1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.96 |
| Profit Margin | 26.7 % |
| Operating Margin | 31.2 % |
| Return on Assets (ttm) | 15.5 % |
| Return on Equity (ttm) | 23.5 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 5.12 |
| Sales Per Share | 6.75 |
| EBITDA (p.s.) | 2.28 |
| Qtrly Earnings Growth | -9.4 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | 47.97 |
| PEG Ratio | 0 |
| Price to Book value | 10.78 |
| Price to Sales | 12.72 |
| Price to Cash Flow | 40.47 |
| Dividend | 0.2 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|